Antineoplaston Precision Therapy Guided by cfDNA Aberrations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet medical need for developing methods of precision cancer treatment, particularly for subjects with terminal cancer, as existing treatments are inadequate in addressing the complexity and diversity of cancer.
Innovation Solution
The use of antineoplastons in pharmaceutical formulations, combined with cell-free DNA (cfDNA) analysis to diagnose and administer precision cancer treatment based on genomic aberrations, thereby achieving tumor and molecular responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then cancer can be treated, but the treatments are inadequate in addressing the complexity and diversity of cancer
Solution Approach 1:
The patent segments cancer treatment into precision-based approaches by analyzing specific genomic aberrations (mutations, amplifications, deletions) in different cancer types. Instead of using uniform conventional treatments, the method divides cancer therapy into targeted interventions based on identified genetic markers, enabling tailored treatment strategies for different patient subgroups.
Solution Approach 2:
The patent applies local quality by customizing treatment approaches based on the specific genomic profile of each patient's cancer. The method identifies and targets specific local genomic aberrations (such as BRCA1/2 mutations in breast cancer or EGFR mutations in lung cancer) rather than applying blanket treatment, thereby addressing the unique characteristics of each patient's disease.
2Reliability
If precision cancer treatment based on genomic aberrations is implemented, then tumor and molecular responses are achieved, but the complexity of diagnosis and treatment selection increases
Solution Approach 1:
The patent performs preliminary genomic analysis and identification of aberrations before treatment selection. By conducting cfDNA testing and genomic profiling in advance, the method pre-determines the appropriate treatment strategy based on identified mutations, amplifications, or deletions, thereby streamlining the subsequent treatment decision-making process.
Solution Approach 2:
The patent incorporates feedback mechanisms through monitoring of tumor response and molecular changes during treatment. The method uses feedback from treatment outcomes and genomic data to adjust and optimize treatment strategies, enabling dynamic adaptation to patient response patterns and improving overall treatment effectiveness.
Data Source
AI summary
Disclosed herein are compositions comprising one or more antineoplastons and using those compositions in methods of treating and/or preventing cancer, prolonging the survival of a subject, and preventing and/or decreasing metastasis of cancer.